About
Profile
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following earl
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
EXEL
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Exelixis Non-GAAP EPS of $0.10 misses by $0.09, revenue of $471.92M misses by $1.47M
- Exelixis Q3 2023 Earnings Preview
- Exelixis gains as Cabometyx patent trial ends (update)
- Exelixis slumps amid Cabometyx patent trial (update)
- Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors
- Exelixis started at buy at Wainwright on targeted oncology pipeline
- Exelixis inks licensing deal with Insilico for tumor candidate
- Exelixis reports positive results for Cabometyx in pancreatic cancer type
- Exelixis appoints Amy Peterson as Chief Medical Officer
- Exelixis lead product hits main goal in Phase 3 prostate cancer trial
- Exelixis Non-GAAP EPS of $0.31 beats by $0.09, revenue of $469.85M beats by $25.02M
- Exelixis Q2 2023 Earnings Preview
- Exelixis, Teva settle patent dispute over cancer drug Cabometyx
- Exelixis sees three Farallon nominees elected to board
- Exelixis a new overweight at Piper Sandler on Cabometyx, pipeline
- Exelixis Non-GAAP EPS of $0.16 misses by $0.06, revenue of $408.8M misses by $13.86M
- Exelixis Q1 2023 Earnings Preview
- Exelixis board member resigns; Farallon gets third board seat in victory
- Exelixis holder Farallon files definitive materials in proxy battle
- Exelixis supports two of Farallon's board nominees as it faces proxy fight